



Micro **MGX**



Jack M. Kloeber, CEO
j-kloeber@micromgx.com



Anthony Goering, CSO
a-goering@micromgx.com

www.micromgx.com

Harnessing
microbial chemistry
to create **more**
effective and
sustainable
products

Problem

Solution



Classic discovery methods have become obsolete.

Time: 6-12 months to examine one strain

Cost: Salary for 1-2 scientists

Risk: 80% Rediscovery!

One of the only large-scale natural product discovery platform

Time: **3 months to examine 1000 strains**


Cost: **Same Salary + \$250,000 analysis**

Risk: **No rediscovery problem**

The MGx Platform


We estimate our platform is more than **100x** more efficient in finding new natural chemicals

1. Flexible – Works with different microbes
2. Massively parallel
3. No rediscovery





The Product

Our product is an Actionable and Enabling Asset Package



Our Business Plan

We are a Discovery and Licensing company



NP Kinect/Cloud-based software


Obtain IP – Baker and Hostetler

Test for different uses/solutions

MGx Platform

A continuous supply of novel chemistry

Through this pipeline, we plan to create a library of Natural Products




The Market

Our Market is B2B licensing to Life Science Companies



**Global Life Sciences
Licensing & Acquisition**



**Only Small Molecules
and Natural Products**



**Plan to achieve 1%
penetration – 5 years
from investment**

*https://clarivate.com/wp-content/uploads/2021/11/JPM-deals-analysis-2019_webinar_FINAL.pdf

Traction

Science supports our platform foundation - Clients support the need and validate the results.




> 500 citations!

7 Peer-Reviewed publications
with new natural products

Fee-for-Service Clients

2019	2020	2021
1 Client	1 Clients	2 Clients
\$ 260,000	\$ 537,000	\$ 523,000



Funds raised to-date

\$ 150,000 SBIR*



\$ 400,000 Angel investment



**A Metabologenomics Platform for Large-Scale, High-Throughput Natural Product Discovery, Jan 6, 2017, SBIR from NIH, #R43AT009417*

1st Patented Product:

MGX-1001 - one of the first in a stream of newly discovered herbicides

The Pipeline Begins

2021 - MGX-1001 is effective against herbicide resistant weeds



Potential?

Blockbuster

Blockbuster

Mustard seedlings (Brassica sp.)



Glyphosate-resistant hairy fleabane

Controls herbicide-resistant weeds

Our Leadership Team

Diverse expertise in a cross-functional organization

Founders



Neil Kelleher, Director
Professor of Chemistry at Northwestern University, Head, Chemistry for Life Sciences Institute
Key Role: Mass Spectrometry



William Metcalf, Chairman
Professor of Molecular Biology at the University of Illinois at Urbana-Champaign.
Key Role: Genome Mining



Regan Thomson, Director
Professor of Chemistry at Northwestern University
Key Role: Organic Synthesis.

Management



Jack M. Kloeber, CEO
Former US Army LTC.
Pharma portfolio management at J&J, BMS.
Owner of R&D decision analysis consulting firm, Kromite.



Anthony Goering, CSO
Co-developed the MGx platform
Expert in methodology for discovering and characterizing natural products.

Investor/ Director



Rajmony Pannu, MD
Board Certified in Vascular, Endo Vascular Medicine
Entrepreneur in Healthcare
Board Director for MetroVein
Healthcare Marketing
Angel Investor

Scientific /Industry Advisors



Richard Baltz, PhD
Discovered daptomycin, last antibiotic to reach the market
Past President/ Fellow of SIMB
Widely read author of Natural Product discovery articles



Alpheus Bingham, PhD
30 yr career in Eil Lilly R&D.
Founded many innovation start ups
Innocentive Founder/CEO
Consultant to Pharma Co's



Joe Byrum, PhD
MBA from Univ of Michigan
Thought leader in AI-Data Sci.
20 yr Leader in Monsanto, Syngenta- Seeds R&D
Financial AI at Principal
Agtech Advisor

Let's put natural product discovery in order



Only a tiny fraction 10's of millions of natural products has been accessed*



MicroMGx is building an organized library of microbes and novel molecules ready for testing and licensing

Efficient + Large Scale + BioActive = Affordable + Accessible + Valuable New Chemicals

*Bérdy, J. "Thoughts and facts about antibiotics: where we are now and where we are heading". J. Antibiot. (Tokyo) 65, 385–395 (2012).



Harnessing
microbial chemistry
to create **more**
effective and
sustainable
products

Contact:

Jack Kloeber CEO

Anthony Goering CSO

www.micromgx.com

| j-kloeber@micromgx.com

| a-goering@micromgx.com